During shortages of Wegovy, Ozempic, Mounjaro, and Zepbound, the FDA exercised temporary enforcement discretion , allowing compounding pharmacies to help meet patient demand. Once manufacturing stabilized: Semaglutide injection products were removed from the FDA Drug Shortage List Tirzepatide injection products were formally declared resolved Compounding reverted to pre-shortage federal and state limits Broad, shortage-based compounding is no longer allowed in 2026
The differences are in consistency batch-to-batch, shelf-life validation, and device convenience, not in whether the drug works
Serious but rare risks include pancreatitis, gallbladder problems , and thyroid concerns
Understanding what to expect during semaglutide withdrawal helps set realistic expectations and prevent panic about a second shedding episode
Cardiovascular disease and risk management: standards of care in diabetes-2024
It also helps counsel and experts assess alternative explanations and known risk factors that could affect causation
